Dr. Brufsky Discusses Future Research into Bisphosphonates

Adam M. Brufsky, MD, PhD
Published: Monday, Aug 11, 2014

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses future research into bisphosphonates.

The cancer cell itself is incredibly complex, Brufsky says. Much work has been done to understand cancer cells with next-generation sequencing and RNA-based assays.

Drugs like bisphosphonates and denosumab affect the host greatly. Research needs to be conducted focused on the genomics of the host and the factors that allow metastatic disease to come about from the host’s perspective.

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses future research into bisphosphonates.

The cancer cell itself is incredibly complex, Brufsky says. Much work has been done to understand cancer cells with next-generation sequencing and RNA-based assays.

Drugs like bisphosphonates and denosumab affect the host greatly. Research needs to be conducted focused on the genomics of the host and the factors that allow metastatic disease to come about from the host’s perspective.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x